Epcoritamab and rituximab for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma confirmed by tissue testing (CD20-positive, grade 1–3A).
- You have not had prior drug treatment for follicular lymphoma (radiation and short steroid bursts may be allowed).
- Your lymphoma must meet at least one “needs treatment now” symptom or scan blood-work pattern (like large nodes, many affected areas, organ problems, B symptoms, or bulky tumors).
- You must be able to safely take study treatment: age 18+, and blood/organ numbers (neutrophils, platelets, kidney and liver tests) must be high enough.
- You must not need urgent chemotherapy right away, and your general strength level must be 0–2 (on the trial’s performance scale).
- You must agree to a tumor biopsy before treatment, and agree to birth control rules or not become pregnant while on the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This trial tests a drug called epcoritamab for people with follicular lymphoma (a type of slow-growing blood cancer) that improved but did not completely go away after standard first therapy. The goal is to see if epcoritamab can help achieve a complete remission.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This trial compares the drug epcoritamab with a 'watch and wait' approach for people with low-tumor-burden follicular lymphoma who have not had treatment before. It tests whether starting treatment early with epcoritamab can improve outcomes.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.